netFormulary
 Report : Medicines with links to NICE 05/03/2021 19:47:19

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Restricted Use NICE TA375: Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying antirheumatic drugs
Abatacept 10.01.03 Restricted Use NICE TA373: Abatcept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abiraterone Actetate 08.03.04.02 Restricted Use NICE TA 259: Abiraterone for castration resistant prostate cancer
Adalimumab 13.05.03 Restricted Use NICE TA 146: Psoriasis-adalimumab
Adalimumab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adalimumab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Adalimumab 10.01.03 Restricted Use NICE TA383: TNF alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
Adalimumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Adefovir Dipivoxil 05.03.03 Non Formulary NICE TA96: Adefovir dipivoxil and pegylated interferon alpha-2a for the treatment of chronic hepatitis B
Aflibercept 11.08.02 Restricted Use NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Restricted Use NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Restricted Use NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Restricted Use NICE TA 294: Macular degeneration (wet age-related) - aflibercept
Alemtuzumab 08.02.03 Restricted Use NICE TA312: Alemtuzumab for treating relapsing-remitting multiple sclerosis
Alirocumab 02.12 Restricted Use NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Restricted Use NICE TA264: Ischaemic stroke (acute) - alteplase
Anakinra 10.01.03 Restricted Use NICE CG79: Rheumatoid arthritis: the management of rheumatoid arthritis in adults
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA 245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apixaban 02.08.02 Formulary NICE TA 341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apomorphine 04.09.01 Restricted Use NG71 Parkinson’s disease in adults
Apremilast 13.05.03 Restricted Use NICE TA 419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Restricted Use NICE TA 433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Non Formulary NICE TA 292: Bipolar disorder (adolescents) - aripiprazole
Aripiprazole 04.02.01 Non Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15-17 years
Atezolizumab 08.02.03 Restricted Use NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.02.03 Restricted Use NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Atezolizumab 08.02.03 Restricted Use NICE TA639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Azacitidine 08.01.03 Non Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Restricted Use NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Bendamustine 08.01.01 Non Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Non Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bivalirudin 02.08.01 Restricted Use NICE TA230: Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02.03 Restricted Use NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03 Non Formulary NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
Bortezomib 08.01.05 Non Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Non Formulary NICE TA129: Multiple myeloma - bortezomib
Botulinum Toxin Type A 04.09.03 Restricted Use NICE TA260: Botox for migraine prophylaxis
Botulinum Toxin Type A 04.09.03 Restricted Use NICE TA 605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Brentuximab vedotin 08.02.03 Restricted Use TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.02.03 Restricted Use TA542 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.02.03 Restricted Use TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brigatinib 08.02 Formulary NICE TA571-Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel 08.01.05 Non Formulary NICE TAG 255: Cabazitaxel for prostate cancer
Capecitabine 08.01.03 Non Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Non Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Non Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Certolizumab Pegol 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis - certolizumab pegol
Certolizumab Pegol 10.01.03 Restricted Use NICE TA 415: Certolizumab Pegol for treating rheumatoid arthritis after an inadequate response to a TNF-alpha inhibitor.
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetuximab 08.01.05 Non Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cinacalcet 09.05.01.02 Non Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.02.04 Restricted Use NICE TA493: Cladribine tablets for treating relapsing-remitting multiple sclerosis
Collagenase clostridium histolytium 10.03.01 Restricted Use NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Dabigatran etexilate 02.08.02 Non Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran etexilate 02.08.02 Non Formulary NICE TA157: Dabigatran etexilate for prevention of venous thromboembolism after hip or knee replacement surgery in adults
Daclizumab 08.02.02 Non Formulary Daclizumab for treating relapsing-remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA597 - Dapagliflozin with insulin for treating type 1 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288 - Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab 08.02.03 Formulary Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.02.03 Formulary Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Dasatinib 08.01.05 Non Formulary NICE TA241:CML for whom treatment with imatinib has failed because of intolerance
Denosumab 06.06.02 Restricted Use NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Restricted Use NICE TA265: Denosumab for the prevention of skeletal-related events in adults with metastases from solid tumours
Dexamethasone 11.04.01 Restricted Use NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dexamethasone 11.04.01 Restricted Use NICE TA349: Dexamethasone intravitreal implant for the treatment of diabetic macular oedema
Dimethyl Fumarate 08.02.04 Restricted Use NICE TA 320: Dimethyl Fumarate for treating relapsing remitting multiple sclerosis
Dimethyl fumarate 13.05.03 Restricted Use NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Docetaxel 08.01.05 Non Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Non Formulary NICE TA109: Breast cancer (early) - docetaxel
Doxorubicin Hydrochloride 08.01.02 Non Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Dupilumab 13.05.03 Restricted Use NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.02.03 Restricted Use NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platimum based chemoradiation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and preventing DVT and PE
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in patients with non-valvular AF
Eltrombopag 09.01.04 Restricted Use NICE TA 293: Thrombocytopenic purpura - Eltrombopag
Empagliflozin 06.01.02.03 Formulary NICE TA336 - Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Encorafenib 08.02 Formulary NICE TA668-Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
Entecavir 05.03.03 Non Formulary NICE TA153: Entecavir for the treatment of chronic hepatitis B
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Erlotinib 08.01.05 Non Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Erlotinib 08.01.05 Non Formulary NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Etanercept 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
Etanercept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 13.05.03 Restricted Use NICE TA103: Psoriasis - efalizumab and etanercept
Everolimus 08.01.05 Non Formulary NICE TA 295: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor)
Everolimus 08.01.05 Non Formulary NICE TA219: Everolimus for second-line treatment of renal cell cancer
Evolocumab 02.12 Restricted Use NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Ezetimibe 02.12 Restricted Use NICE TA132: Hypercholesterolaemia - ezetimibe
Febuxostat 10.01.04 Restricted Use NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms in men
Fingolimod 08.02.04 Restricted Use NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Non Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Non Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fluocinolone 11.04.01 Restricted Use NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of TA271)
Fremanezumab 04.07.04.02 Restricted Use NICE TA631-Fremanezumab for preventing migraine
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib 08.01.05 Non Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Non Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Non Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gilteritinib 08.02 Formulary NICE TA642-Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 10.01.03 Restricted Use NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis - golimumab
Golimumab 10.01.03 Restricted Use NICE TA329: Ulcerative colitis - golimumab
Golimumab 10.01.03 Restricted Use NICE TA383: Ankylosing spondylitis - golimumab
Golimumab 10.01.03 Restricted Use NICE TA225: Rheumatoid arthritis treatment after conventional DMARDs - golimumab
Guselkumab 13.05.03 Restricted Use NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Imatinib 08.01.05 Non Formulary NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Non Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 08.01.05 Non Formulary NICE TA70: Leukaemia (chronic myeloid) - imatinib
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderatley to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Infliximab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
Infliximab 10.01.03 Restricted Use NICE TA383: TNF alpha inhibitors for ankylosing spondylitis and non-radiologic axial spondyloarthritis
Infliximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 13.05.03 Restricted Use NICE TA134: Infliximab for psoriasis
Inotuzumab ozogamicin 08.02.03 Restricted Use NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Isatuximab 08.02.03 Restricted Use NICE TA658-Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Ivabradine 02.06.03 Restricted Use NICE TA267: Ivabradine for treating chronic heart failure
Ixekizumab 10.01.03 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 13.05.03 Restricted Use NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lorlatinib 08.01 Non Formulary Lorlatinib for previously treated ALK +VE ADVANCED nsclc
Lorlatinib 08.02 Formulary Previously treated ALK +ve advanced NSCLC NICE TA 628
Lubiprostone 01.02 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Mannitol inhalation 03.07 Non Formulary NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis
Mepolizumab 03.04.02 Restricted Use NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Mirabegron 07.04.02 Non Formulary NICE TA 290: Overactive bladder - mirabegron
Naltrexone Hydrochloride 04.10.03 Non Formulary NICE TA115: Naltrexone for the management of opioid dependence
Natalizumab 08.02.04 Restricted Use NICE TA127: Multiple sclerosis - natalizumab
Nilotinib 08.01.05 Non Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Niraparib 08.02 Formulary NICE TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Niraparib 08.02 Formulary NG161-COVID-19 rapid guideline: delivery of systemic anticancer treatments
Niraparib 08.02 Formulary NICE TA673-Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Obinutuzumab 08.02.03 Restricted Use NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab 08.02.03 Restricted Use NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
Ocrelizumab 08.02.03 Restricted Use NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab 08.02.03 Restricted Use NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ofatumumab 08.02.03 Restricted Use NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Olaparib 08.02 Formulary TA598- Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaparib 08.02 Formulary TA620-Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Olaparib 08.02 Formulary NG161-COVID-19 rapid guideline: delivery of systemic anticancer treatments
Omalizumab 03.04.02 Restricted Use NICE TA278: Omalizumab for treating severe persistant allergic asthma (review of TA133 and TA201)
Omalizumab 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Osimertinib 08.02 Formulary NICE TA654 Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Non Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Non Formulary NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel 08.01.05 Non Formulary NICE TA108: Breast cancer (early) - paclitaxel
Patiromer 09.02.01.01 Restricted Use Patiromer for treating hyperkalaemia TA623
Pazopanib 08.01.05 Non Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration.
Peginterferon Alfa 08.02.04 Restricted Use NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Peginterferon Alfa 08.02.04 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Pemetrexed 08.01.03 Non Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Non Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Non Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pentosan Polysulphate 07.04.03 Formulary NICE TA 610
Pimecrolimus 1% cream 13.05.03 Restricted Use NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Polatuzumab vedotin 08.02.03 Restricted Use TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
Prasugrel 02.09 Restricted Use NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182)
Prucalopride 01.06.07 Restricted Use NICE TA211: Prucalopride for the treatment of chronic constipation in women
Raloxifene Hydrochloride 06.04.01.01 Non Formulary NICE quick reference guide on osteoporosis
Ranibizumab 11.08.02 Restricted Use NICE TA283: macular oedema secondary to retinal vein occlusion
Ranibizumab 11.08.02 Restricted Use NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathlogical myopia
Ranibizumab 11.08.02 Restricted Use NICE TA155: age-related macular degeneration
Ranibizumab 11.08.02 Restricted Use NICE TA274: diabetic macular oedema
Reslizumab 03.04.02 Restricted Use NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Restricted Use NICE TA232 - Retigabine for the adjunctive treatment of partial onset seizures in epilepsy
Ribavirin 05.03.05 Non Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Ribavirin 05.03.05 Non Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Ribavirin 05.03.05 Non Formulary NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Ribavirin 05.03.05 Non Formulary NICE TA75: Interferon alfa and ribavirin for the treatment of chronic hepatitis C
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy.
Riluzole 04.09.03 Restricted Use NICE TA20: Motor neurone disease - riluzole
Rituximab 08.02.03 Restricted Use NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Restricted Use NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab 08.02.03 Restricted Use NICE TA137: Lymphoma (follicular non-Hodgkins) - rituximab
Rituximab 08.02.03 Restricted Use NICE TA110: Follicular lymphoma - rituximab Non-Hodgkins lymphoma - rituximab
Rituximab 10.01.03 Restricted Use NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in patients with AF
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for treatment of DVT
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA287: Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban: guidance
Roflumilast 03.03.03 Restricted Use NICE TA461: Roflumilast for treating severe chronic obstructive pulmonary disease
Romiplostim 09.01.04 Restricted Use NICE TA221: Thrombocytopenic purpura - romiplostim
Rucaparib 08.02 Formulary NICE TA 611
Rucaparib 08.02 Formulary NG161COVID-19 rapid guideline delivery of systemic anticancer treatments
Ruxolitinib 08.01.05 Non Formulary NICE TA 289: Myelofibrosis (splenomegaly, symptoms) - ruxolitinib
Safinamide 04.09.01 Restricted Use NICE ES6 - Parkinson’s disease with motor fluctuations: safinamide
Sarilumab 10.01.03 Restricted Use COVID-19 rapid evidence summary: Sarilumab for COVID-19-ES34
Sarilumab 10.01.03 Restricted Use NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Restricted Use NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 13.05.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Restricted Use NICE TA407: Secukinumab - active ankylosing spondylitis
Semaglutide 06.01.02.03 Formulary NG28- Type 2 diabetes in adults: management
Sodium Zirconium Cyclosilicate 09.02.01.01 Restricted Use Sodium zirconium cyclosilicate for treating hyperkalaemia
Somatropin 06.05.01 Restricted Use NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Restricted Use NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sunitinib 08.01.05 Non Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Non Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Non Formulary NICE TA178: Renal cell carcinoma
Tacrolimus ointment 13.05.03 Restricted Use NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03 Non Formulary NICE TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C
Temozolomide 08.01.05 Non Formulary NICE TA23: Brain cancer - temozolomide
Temozolomide 08.01.05 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.01 Restricted Use NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B
Teriflunomide 08.02.04 Restricted Use NICE TA 303: Teriflunomide for treating relapsing remitting multiple sclerosis
Thalidomide 08.02.04 Restricted Use NICE TA228 - Multiple Myeloma (first line) - bortezomib and thalidomide
Ticagrelor 02.09 Restricted Use NICE TA236 - Acute Coronary Syndromes - Ticagrelor
Ticagrelor 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Restricted Use
Tildrakizumab 13.05.03 Restricted Use
Tocilizumab 10.01.03 Restricted Use NICE TA238: Tocilizumab for the treatment of systemic juvenile arthritis
Tocilizumab 10.01.03 Restricted Use COVID-19 rapid evidence summary: Tocilizumab for COVID-19 ES33
Tocilizumab 10.01.03 Restricted Use NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab 10.01.03 Restricted Use Tocilizumab for Giant Cell Arteritis TA518
Tocilizumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idopathic arthritis
Tofacitinib 01.05.03 Restricted Use NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib 10.01.03 Restricted Use NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 10.01.03 Restricted Use NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tolvaptan 06.05.02 Non Formulary NICE TA358: Tolvapton for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Non Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA91: Topotecan for ovarian cancer
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Non Formulary NICE TA222- ovarian cancer
Trastuzumab 08.01.05 Non Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Non Formulary NICE TA34: Breast cancer - trastuzumab
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 01.05.03 Formulary Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab 10.01.03 Restricted Use NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Restricted Use NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Restricted Use NICE TA180: Psoriasis - ustekinumab
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Restricted Use NICE TA352: Vedolizumab for treating moderately to severely active crohns disease after prior therapy
Vedolizumab 01.05.03 Restricted Use NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Venetoclax 08.02 Formulary NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
Venetoclax 08.02 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.02 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Zolpidem 04.01.01 Non Formulary NICE TAG 77 : Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Restricted Use NICE TA77 :Zaleplon, zolpidem and zopiclone for the management of insomnia
The Mid Yorkshire Hospitals